At present, the global medical and health care industry's R&D, production and sales map is accelerating to reconfigure, and technological innovation is leading the golden age of life sciences. AI new drug development, cell and gene therapy technologies strongly help biomedicine and clinical treatment break through the shackles and release strong innovative vitality.
On December 13, 2021, VB100-2021 (Future Medical 100) and Artery.com released the list of "2021 Biomedical Value Domains". Among a group of high-growth companies, Help Therapeutics was ranked in the Top 10 of the 2021 Biomedical Value Domains - Cell and Gene Therapy.
The selection is based on a comprehensive assessment of the four dimensions of corporate growth: core competitiveness, key partners, industry performance and innovation vitality, complemented by the annual innovation performance of companies in terms of R&D teams, R&D investment, R&D methods, progress of products under development and marketed products, etc. The selection is based on two value areas, AI+ drug development and cell and gene therapy, to produce the "2021 Biopharmaceutical Value Area List".
With outstanding industry influence, continuous innovation and breakthrough growth, Help Therapeutics was ranked in the TOP 10 of the 2021 Biomedical Value Sector List - Cell and Gene Therapy, which is not only a high recognition of the company's R&D strength and industry status, but also a confirmation of the company's focus on developing iPS cell therapy drug technology.
According to McKinsey data, by 2020, 16 of the world's top 20 pharmaceutical companies will have laid out their R&D pipeline for cellular gene therapy, and cellular and gene therapy will gradually enter the commercialization stage from the hot concept. With the continuous empowerment of capital, the market value is expected to exceed 100 billion in the next 5 years; the industry synergy will deepen, providing "whole life cycle" protection for patients with tumors, rare diseases and various genetic diseases. Help Therapeutics would like to join hands with all "biomedical innovators" to jointly promote the development of biomedical field and open a new era of biomedical industry.